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ABSTRACT
Background: We evaluated the characteristics of late-onset asthma in elderly patients with asthma, particu-
larly concerning the relationship of IgE mediation and response to treatment.
Methods: This study included asthma patients aged 60 or older who were hospitalized under a clinical path-
way that provided the treatment of asthma exacerbation, thorough examination, and patient education simulta-
neously. The patients were divided into two groups, those in whom asthma developed at age 60 or older (late-
onset group) and those in whom asthma developed before age 60 (early-onset group). Both groups received
step-down therapy with fluticasone dry powder after discharge, and asthma severity was compared between
two time points: at 1 year and 2 years after the start of treatment.
Results: One-third of all patients with asthma were aged 60 or older, and half of these had late-onset asthma.
There was an inverse correlation between serum IgE levels and the age of onset. The positive rates of specific
IgE antibodies to Japanese cedar pollen or house dust mite were significantly lower in the late-onset group than
in the early-onset group. Pulmonary functions were equivalent between the two groups. However, asthma se-
verity on admission was lower in the late-onset group. Response to treatment was better in the late-onset
group, especially at 1 year of treatment.
Conclusions: Asthma in elderly patients may be divided into early-onset persistent asthma and late-onset
asthma with short duration. Late-onset asthma is less IgE-mediated, less severe, and has a better prognosis
after appropriate treatment with inhaled fluticasone, and patients are more likely to drop out. For elderly pa-
tients with asthma, early detection, repetitive patient education and early intervention with inhaled corticosteroid
therapy are important.
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INTRODUCTION
With the recent rapid aging of the population, we are
seeing an increasing number of elderly patients with
asthma. The incidence of asthma has been reported
to increase with age.1 As previously reported,2 some
elderly patients have early-onset asthma that is se-
vere and persists for a prolonged period , whereas
other elderly patients have late-onset asthma that
lasts for a short period. We speculated that there may
be some differences in the clinical features between
the two groups. In other words, since the duration of
asthma is shorter in the late-onset group, better re-
sponse to treatment was expected . In the present
study, we compared the characteristics of late-onset
asthma with those of early-onset asthma in elderly pa-
tients. We also examined whether there was any dif-
ference in efficacy of inhaled corticosteroid treatment
between the two groups under the same therapeutic
strategy.
METHODS
Of 328 asthma patients admitted to our hospital and
managed under a clinical pathway of bronchial
asthma from 1998 through 2004, 109 patients aged 60
years or older were included in this study. All pa-
tients met the American Thoracic Society criteria for
asthma. None of the patients were instructed until
hospitalization to regularly take inhaled corticoster-
oids (ICS) at their appropriate dosage. The clinical
Allergology International. 2005;54:543-546
ORIGINAL ARTICLE
1Department of Respiratory Medicine, Takatsuki Red Cross Hospi-
tal, Osaka, Japan.
Correspondence: Hirotaka Yasuba M.D., Department of Respira-
tory Medicine, Takatsuki Red Cross Hospital, Abuno 1−1−1,
Takatsuki city, Osaka 569−1045, Japan.
Email: hyacchan@ga2.so―net.ne.jp
Received 19 January 2005. Accepted for publication 12 April
2005.
2005 Japanese Society of Allergology
Allergology International Vol 54, No4, 2005 www.jsaweb.jp 543
Fig. 1 The relationship between serum IgE levels and age 
of onset in al elderly asthma patients aged 60 or older. 
There was a significant negative corelation between the 
two variables (r＝−0.415, p＜0.0001).
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Table 1 Profiles of the two patient groups, the late-onset group (onset over 60) and the early-onset group (onset under 60). 
The duration of asthma was significantly shorter and serum IgE levels were significantly lower in the patients with onset over 60.
onset under 60onset over 60
n.s.58 (21/37)51 (18/33)no. of cases (M/F)
p＜0.00165.9 ± 6.771.0 ± 6.7age
no. of smoker
n.s.32/23/328/20/3never/ex-/curent
p＜0.000123.8 ± 2.3 3.1 ± 0.4duration of asthma (y)
p＜0.01 569 ± 105242 ± 45serum IgE level (IU/mL)
n.s.1510no. of alergic rhinitis
n.s.59.0 ± 2.265.0 ± 2.0FEV1.0/VCpred. (%)
n.s.127 ± 6 123 ± 4 RV/TLC %pred. (%)
mean ± S.E. 
pathway of patients who were admitted with moder-
ate or severe asthma exacerbations (defined by the
2002 GINA Guidelines ) consisted of simultaneous
treatment of asthma exacerbations, thorough exami-
nation, and education for an eight-day period. At the
time of discharge, improvement in FEV1.0 by 20% or
more as compared with that at admission, and chest
CT showing no low attenuation areas were con-
firmed.
After completion of the clinical pathway during the
hospital stay, the patients received step-down therapy
with ICS (fluticasone propionate dry powder) on an
outpatient basis. During the hospital stay, the patients
were given careful instructions on how to inhale corti-
costeroids . The dose of fluticasone was decreased
stepwise every 4 months from 800 to 600, 400, 300,
200, and 100 μgday after discharge if the asthma
condition remained ‘totally controlled’ or ‘well con-
trolled’.3 In the case of the occurrence of an asthma
exacerbation during dose reduction , systemic ster-
oids could be used and fluticasone was increased to
the previous dose. As concomitant therapy, theophyl-
line andor pranlukast andor salmeterol were used
until the dose of fluticasone reached 200 μgday. Sal-
butamol was used as a reliever. Those whose asthma
was poorly controlled with these treatments received
oral methylprednisolone. Asthma severity was rated
according to the 2002 GINA Guidelines by three aller-
gology specialists. Severity was scored with 1 to 4
points given to steps 1 to 4, respectively , and the
scores were compared.
RESULTS
Of 328 patients with bronchial asthma who success-
fully completed the clinical pathway , 109 patients
(33%) were aged 60 or older. Of these, 51 (47%) had
late-onset asthma (onset at age 60 or older) and 58
(53%) had early-onset asthma (onset before age 60);
no significant differences were found between the
groups in terms of gender ratio and the number of
‘never smokers’ (Table 1) . The duration of asthma
was markedly shorter in the early-onset group (3.1 ±
0.4 years) than in the late-onset group (23.8 ± 2.3
years). Serum IgE levels were significantly lower in
the late-onset group (242 ± 45 IUmL) than in the
early-onset group (569 ± 105 IUmL). With regard to
pulmonary function , there were no differences in
FEV1.0VCpred or RVTLC (% pred) between the two
groups. Among patients aged 65 or older, there was
no difference in mean age (72.9 ± 6.2 vs. 71.0 ± 5.6, n.
s.) but serum IgE was significantly lower in patients
in the late-onset group (199.4 ± 44.7 vs. 553.6 ± 173.8,
p < 0.05). Statistical analysis was performed using the
Mann-Whitney U test.
The relationship between serum IgE levels and age
of onset in all patients aged 60 or older is shown in
Figure 1. There was a significant negative correlation
between the two variables (r = −0.415, p < 0.0001 by
Pearson’s correlation and p = 0.0012 by Spearman’s
correlation). The correlation coefficient between the
logarithmic value of IgE and age of onset was
r = −0.339 (p = 0.0006 by Pearson’s correlation and p =
0.0012 by Spearman’s correlation).
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Fig. 2 The positive rates of specific IgE antibodies to com-
mon alergens in Japan.‘Molds’is a multialergen of 6 speci-
es, and‘cat or dog’is a multialergen of 5 species of animal 
epithelium. The positive rates of specific IgE antibodies to 
Japanese Cedar polen and house dust mite (D.f) were sig-
nificantly lower in the late-onset group.
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Fig. 3 The course of asthma severity in patients who con-
tinued to receive treatment for 2 years. In the late-onset 
group, severity showed a significant decrease at 1 year, and 
a further decrease at 2 years. In the early-onset group, 
there was no significant improvement at 1 year, but a signifi-
cant decrease was seen finaly at 2 years. Severity was 
lower in the late-onset group than in the early-onset group. 
(* p＜0.01, ** p＜0.001, *** p＜0.0001)
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Figure 2 shows the positive rates of specific IgE an-
tibodies to common allergens in Japan. The positive
rates of specific IgE antibodies to Japanese Cedar pol-
len and house dust mite (D.f), unlike other allergens,
were significantly lower in the late-onset group (χ2
test).
Table 2 shows the outcomes after step-down ther-
apy . Asthma severity was expressed in numbers ,
based on the severity ratings, steps 1 to 4. Severity at
the time of admission was significantly lower in the
late-onset group. The same tendency was also seen at
1 and 2 years after the start of treatment. Statistical
analysis was performed using the Mann-Whitney U
test. The dropout ratio was significantly greater in the
late-onset group (χ2 test). A dropout case is a case in
which asthma severity cannot be judged accurately
for a year due to the patient’s failure to regularly visit
the hospital. Thirty-four dropout patients stopped vis-
iting the hospital regularly because of marked de-
creases in the severity of their asthma symptoms .
Some of these continued being seen by other physi-
cians for treatment of other diseases. In 8 dropout pa-
tients the reason was unknown.
Figure 3 shows the course of asthma severity in pa-
tients who continued to receive treatment for 2 years.
In the late-onset group, severity showed a significant
decrease at 1 year (p < 0.01), and a further decrease
at 2 years (p < 0.0001). Meanwhile, there was no sig-
nificant improvement at 1 year in the early-onset
group, but a significant decrease was seen finally at 2
years (p < 0.0001) (Fisher’s PLSD) . Severity was
lower in the late-onset group than in the early-onset
group (p < 0.0001, repeated measures ANOVA).
DISCUSSION
In this study , we found an inverse correlation be-
tween IgE levels and age of onset in elderly asthma
patients as a whole. Moreover, IgE levels were lower
in the late-onset group. This may be explained by less
sensitivity to common allergens such as Japanese Ce-
dar pollen and house dust mite as shown in Figure 2.
As previously reported,4 IgE mediation was thought
to be less frequent in the late-onset group . Other
mechanisms than IgE mediation may be important
for stimulating Th2 cells in elderly onset asthma.
We have been applying a step-down therapy with
ICS as early as possible in elderly asthma patients as
the basic strategy, as well as in younger asthma pa-
tients . As in the GOAL study , 3 our treatment has
been aimed at achieving the guideline-defined total
control of asthma. As a result, response to such treat-
ment in the late-onset group was better than that in
the early-onset group; severity at onset was lower ,
and more rapid improvement in the severity was
shown 1 year after the start of treatment. The primary
reason for this is that the duration of asthma from on-
set is shorter and intervention with ICS is earlier .
Since airway wall remodeling is induced by chronic
airway inflammation, it is important to start ICS ther-
apy as soon as possible.5,6 Early and long term inter-
vention with ICS can prevent airway remodeling.7 As
in other age groups , early intervention with ICS
seems to play a key role also in elderly asthma pa-
tients.
In this study we applied a new analysis comparing
the ‘severity steps’ with the results of longstanding
step-down therapy because the guidelines aimed to
achieve the step-down of severity if possible . The
lung function or symptom score alone were not differ-
ent between the two groups, because the classifica-
tion of severity was based on both ‘symptoms and
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Table 2 The prognosis after step-down therapy of fluticasone. Asthma severity was expressed in numbers, based on the se-
verity ratings, steps 1 to 4. Severity at the time of admission, 1 and 2 years later was significantly lower in the late-onset group. 
Dropout was greater in the late-onset group.
onset under 60 y.o.onset over 60 y.o.
p＜0.0023.16 ± 0.05 (n＝58)2.90 ± 0.05 (n＝51)start
p＜0.00013.02 ± 0.08 (n＝54)2.50 ± 0.10 (n＝34)1 year later
p＜0.0052.73 ± 0.11 (n＝51)2.21 ± 0.14 (n＝29)2 year later
mean ± S.E.
dropout
p＜0.0054161 year later
p＜0.055172 year later
 (n)
lung function step’ and ‘current treatment step’, and
because we tried to maintain the condition totally or
well controlled in all patients even if using oral corti-
costeroids in severe cases.
In this study , 33% of all asthma inpatients were
aged 60 or older, and 16% had asthma with onset at
age 60 or older. In a Japanese report in 1991,8 36%
were aged 60 or older and 12% had asthma with onset
at age 60 or older. It is thought that in many cases, an
appropriate diagnosis is not made in elderly asth-
matic patients and less patients are receiving appro-
priate treatment , which is one of the reasons why
asthma death in elderly patients has not decreased.9
We need to promote appropriate diagnosis and early
detection of asthma in the elderly in the future.
However , it is noteworthy that in the late-onset
group there were many dropouts, as shown in Table
2. The reasons for this may include a lack of under-
standing and various complications due to advanced
age. In order to improve the prognosis of asthma in
elderly patients, the use of potent ICS associated with
good compliance such as fluticasone dry powder and
the promotion of patient education with the use of a
clinical pathway or other method are thought to be
important.
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